President, Astellas Pharma US
Mark Reisenauer is President of Astellas Pharma US, an affiliate of the Tokyo-based pharmaceutical company headquartered in Northbrook, Ill., with 1,000 employees. Astellas is dedicated to improving the health of people around the world by turning innovative science into value for patients. In his role, Reisenauer is leading efforts to advance the company’s priorities to pioneer first-in-class health solutions in oncology and medical specialties, including women’s health, infectious disease, immunology, and urology.
Reisenauer was most recently Senior Vice President of Astellas’ Oncology business unit and joined Astellas in 2011 as Vice President of Oncology Sales and Marketing. During his tenure, his leadership helped bring new important oncology medicines to patients, including XTANDI® (enzalutamide), XOSPATA® (gilteritinib) and PADCEV® (enfortumab vedotin-ejfv), all of which have become standards of care in their approved indications. Oncology is now Astellas’ largest disease area of focus. In the U.S., Reisenauer is helping to lead the company’s commitment to change the course of cancer treatment by pursuing targeted therapies for hard-to-treat cancers where few therapies exist for patients who need it most. Inspired by his personal experience caring for his father with cancer, Reisenauer also spearheaded the creation of the Astellas Oncology C3 (Changing Cancer Care) Prize, a global challenge launched in 2016 that funds and advances the best non-treatment ideas to improve cancer care for patients, caregivers, and the broader oncology community.
Reisenauer has dedicated his career to creating change that positively impacts the lives of patients and their caregivers. Prior to joining Astellas, he served as Senior Vice President and Chief Commercial Officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning, and commercial launch planning. Previously, he held various sales and marketing leadership roles at AstraZeneca, Bristol Myers Squibb, Pharmacia, and Abbott. Reisenauer earned a bachelor’s degree in political science from the University of Wisconsin.
Reisenauer serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization dedicated to advancing policies that help ensure a constructive environment for biopharmaceutical innovation while also supporting affordable access to patients.
